Penny L Moore1, Carolyn Williamson. 1. aCentre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory ServicebFaculty of Health Sciences, University of the Witwatersrand, JohannesburgcCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, DurbandDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town; NHLS, Cape Town, South Africa.
Abstract
PURPOSE OF REVIEW: A vaccine that elicits antibody responses that can neutralize the diversity of HIV clades has not yet been achieved, and is a major focus of HIV vaccine research. Here, we provide an update on the barriers to eliciting such antibodies, and how advances in immunogen design may circumvent these roadblocks, focusing on data published in the last year. RECENT FINDINGS: Studies of how broadly neutralizing antibodies (bNAbs) develop in HIV-infected donors continue to produce key insights, suggesting that for some viral targets there are common pathways to developing breadth. Germline-targeting strategies, that aim to recruit rare precursors of bNAbs, have shown promise in immunogenicity studies, and structural biology has led to advances in immunogen design. Mapping of strain-specific tier 2 vaccine responses has highlighted the challenges that remain in driving antibodies toward breadth. SUMMARY: Elucidation of the HIV envelope structure, together with an understanding of how bNAbs emerge in vivo has guided the design of new immunogens and vaccine strategies that show promise for eliciting protective antibodies.
PURPOSE OF REVIEW: A vaccine that elicits antibody responses that can neutralize the diversity of HIV clades has not yet been achieved, and is a major focus of HIV vaccine research. Here, we provide an update on the barriers to eliciting such antibodies, and how advances in immunogen design may circumvent these roadblocks, focusing on data published in the last year. RECENT FINDINGS: Studies of how broadly neutralizing antibodies (bNAbs) develop in HIV-infected donors continue to produce key insights, suggesting that for some viral targets there are common pathways to developing breadth. Germline-targeting strategies, that aim to recruit rare precursors of bNAbs, have shown promise in immunogenicity studies, and structural biology has led to advances in immunogen design. Mapping of strain-specific tier 2 vaccine responses has highlighted the challenges that remain in driving antibodies toward breadth. SUMMARY: Elucidation of the HIV envelope structure, together with an understanding of how bNAbs emerge in vivo has guided the design of new immunogens and vaccine strategies that show promise for eliciting protective antibodies.
Authors: Rui Kong; Kai Xu; Tongqing Zhou; Priyamvada Acharya; Thomas Lemmin; Kevin Liu; Gabriel Ozorowski; Cinque Soto; Justin D Taft; Robert T Bailer; Evan M Cale; Lei Chen; Chang W Choi; Gwo-Yu Chuang; Nicole A Doria-Rose; Aliaksandr Druz; Ivelin S Georgiev; Jason Gorman; Jinghe Huang; M Gordon Joyce; Mark K Louder; Xiaochu Ma; Krisha McKee; Sijy O'Dell; Marie Pancera; Yongping Yang; Scott C Blanchard; Walther Mothes; Dennis R Burton; Wayne C Koff; Mark Connors; Andrew B Ward; Peter D Kwong; John R Mascola Journal: Science Date: 2016-05-13 Impact factor: 47.728
Authors: Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber Journal: AIDS Date: 2014-01-14 Impact factor: 4.177
Authors: Michela Locci; Colin Havenar-Daughton; Elise Landais; Jennifer Wu; Mark A Kroenke; Cecilia L Arlehamn; Laura F Su; Rafael Cubas; Mark M Davis; Alessandro Sette; Elias K Haddad; Pascal Poignard; Shane Crotty Journal: Immunity Date: 2013-09-12 Impact factor: 31.745
Authors: Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris Journal: Nat Med Date: 2012-10-21 Impact factor: 53.440
Authors: Jean-Philippe Julien; Jeong Hyun Lee; Gabriel Ozorowski; Yuanzi Hua; Alba Torrents de la Peña; Steven W de Taeye; Travis Nieusma; Albert Cupo; Anila Yasmeen; Michael Golabek; Pavel Pugach; P J Klasse; John P Moore; Rogier W Sanders; Andrew B Ward; Ian A Wilson Journal: Proc Natl Acad Sci U S A Date: 2015-09-08 Impact factor: 11.205
Authors: Jinal N Bhiman; Colin Anthony; Nicole A Doria-Rose; Owen Karimanzira; Chaim A Schramm; Thandeka Khoza; Dale Kitchin; Gordon Botha; Jason Gorman; Nigel J Garrett; Salim S Abdool Karim; Lawrence Shapiro; Carolyn Williamson; Peter D Kwong; John R Mascola; Lynn Morris; Penny L Moore Journal: Nat Med Date: 2015-10-12 Impact factor: 53.440
Authors: Claus Kadelka; Thomas Liechti; Hanna Ebner; Merle Schanz; Peter Rusert; Nikolas Friedrich; Emanuel Stiegeler; Dominique L Braun; Michael Huber; Alexandra U Scherrer; Jacqueline Weber; Therese Uhr; Herbert Kuster; Benjamin Misselwitz; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Roger D Kouyos; Huldrych F Günthard; Alexandra Trkola Journal: J Exp Med Date: 2018-05-24 Impact factor: 14.307